Klotho Neurosciences, INC 8-K filings

Greenland Mines Ltd. has adjourned its Special Meeting of Stockholders for the third time, now scheduled for September 3, 2026, with no business conducted at the August 7th reconvened meeting.

Greenland Mines Ltd. has adopted a limited-duration stockholder rights plan to protect shareholder value and ensure fair treatment in potential acquisition scenarios.

Greenland Mines Ltd. announced the adjournment of its special meeting of stockholders to August 7, 2026, following the approval of an adjournment proposal.

Greenland Mines Ltd. announced a significant upgrade to its Skaergaard precious and critical metals project, with a new S-K 1300-compliant report showing a 31% increase in indicated PdEq ounces and a 36% grade uplift.

Greenland Mines Ltd. announced the termination of its At-the-Market Sales Agreement with A.G.P./Alliance Global Partners, effective July 4, 2026.

Greenland Mines Ltd. has dismissed BCRG Group as its independent auditor and appointed Simon & Edward LLP, effective June 23, 2026.

Greenland Mines Ltd. has successfully closed a private placement of 15,000,000 shares of common stock, raising approximately $3.75 million in gross proceeds.

Greenland Mines Ltd. announced a $3.75 million private placement of common stock to fund working capital and general corporate purposes.

Greenland Mines Ltd announced a definitive agreement to merge with Neo North Star Resources, Inc., involving a cash and stock consideration of $35 million.

Greenland Mines Ltd. filed an amendment to its Form 8-K, clarifying that financial statements for the acquired Greenland Mines, Inc. assets are not required as they do not constitute a business under Regulation S-X.

Greenland Mines Ltd details development plans for its Skaergaard PGM-Au-V-Ga-Fe-Ti project in East Greenland, highlighting its strategic importance for critical minerals.

Greenland Mines Ltd. announced the immediate appointment of Jason D. Sawyer to its Board of Directors, effective April 17, 2026.

Greenland Mines Ltd. has secured an additional 180-day extension from Nasdaq to regain compliance with the minimum $1 bid price requirement, pushing the deadline to September 14, 2026.

Klotho Neurosciences rebrands to Greenland Mines Ltd, shifts focus to natural resources while retaining biotech division.

Greenland Mines Ltd, formerly Klotho Neurosciences, Inc., announced the acquisition of Greenland Mines and its world-class Skaergaard gold and PGM project, valued at $68 billion.

Klotho Neurosciences has acquired Greenland Mines Corp., gaining control of a $68 billion palladium, gold, and platinum deposit in Greenland and plans to rebrand.

Klotho Neurosciences, Inc. announced the closing of a private placement, raising approximately $7.75 million through the issuance of common stock and warrants.

Klotho Neurosciences, Inc. announced a private placement of common stock, warrants, and notes, raising approximately $9.38 million from 10 investors.

Klotho Neurosciences, Inc. has entered into an agreement to sell $14.96 million in Series C Preferred Stock to investor Sigma9 Capital, Ltd. in a private offering.

Klotho Neurosciences, Inc. received a Nasdaq delinquency notice for failing to maintain its minimum bid price, initiating a 180-day compliance period.

Klotho Neurosciences, Inc. has amended its forward purchase agreement with Meteora entities, extending the valuation date and fixing the maximum number of shares.

Klotho Neurosciences, Inc. has entered into a binding agreement with AAVnerGene Inc. to initiate manufacturing and development of its KLTO-202 gene therapy candidate using AAVnerGene's AAVone platform technology.

Klotho Neurosciences, Inc. filed an amendment to its August 30, 2024, 8-K report to correct the effective date of Edward Cong Wang's resignation from its Board of Directors to August 26, 2024.

Klotho Neurosciences, Inc. has entered into an exclusive global agreement with AAVnerGene Inc. to utilize its AAVone platform for the development and commercialization of three human Klotho gene therapy programs.

Klotho Neurosciences, Inc. announced it has regained full compliance with Nasdaq's minimum bid price and stockholders' equity requirements, while also transferring its listing from the Nasdaq Global Market to the Nasdaq Capital Market.

Klotho Neurosciences, Inc. announced that its investigational gene therapy, KLTO-202, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of Amyotrophic Lateral Sclerosis.

Klotho Neurosciences, Inc. announced the commencement of manufacturing for its investigational gene therapy KLTO-202, targeting Amyotrophic Lateral Sclerosis, with clinical trials anticipated to begin by the third quarter of next year.

Klotho Neurosciences, Inc. announced it raised over $11 million through warrant exercises, extinguished all outstanding debt, and believes it now meets Nasdaq's stockholders' equity requirements.

Klotho Neurosciences, Inc. announced the mutual termination of its Share Exchange Agreement to acquire SB Security Holdings, LLC from SkyBell Technologies, Inc., while simultaneously disclosing a new $500,000 private placement of Series B Preferred Stock.

Klotho Neurosciences, Inc. has announced a temporary repricing of its public warrants to $1.35 to encourage exercise, alongside a correction to a previously reported $500,000 private placement, now stating 6,250,000 shares were sold.